1. Identifying Hub Genes Associated with Neoadjuvant Chemotherapy Resistance in Breast Cancer and Potential Drug Repurposing for the Development of Precision Medicine
   Trishna Saha Detroja et al, 2022, International Journal of Molecular Sciences CrossRef
2. Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells
   Kyu Sic You et al, 2021, Cancers CrossRef
3. RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma
   Yanfang Jiang et al, 2024, Investigational New Drugs CrossRef
4. RPTOR blockade suppresses brain metastases of NSCLC by interfering the ceramide metabolism via hijacking YY1 binding
   Ying Lin et al, 2024, Journal of Experimental & Clinical Cancer Research CrossRef
5. Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?
   Yong Weon Yi et al, 2021, International Journal of Molecular Sciences CrossRef
6. The EGFR Polymorphism Increased the Risk of Hepatocellular Carcinoma Through the miR-3196-Dependent Approach in Chinese Han Population
   Li Zhang et al, 2021, Pharmacogenomics and Personalized Medicine CrossRef
7. Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
   Kyu Sic You et al, 2021, Pharmaceuticals CrossRef
8. Identifying Key Lysosome-Related Genes Associated with Drug-Resistant Breast Cancer Using Computational and Systems Biology Approach
   Aref Shiralipour et al, 2022, Iranian Journal of Pharmaceutical Research CrossRef
9. Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins
   Jing Ma et al, 2023, Breast Cancer: Targets and Therapy CrossRef
10. Bisphenol S and Epidermal Growth Factor Receptor Signaling in Human Placental Cytotrophoblasts
    Elvis Ticiani et al, 2021, Environmental Health Perspectives CrossRef